25 novembre 2009

Auteurs :
Référence : Prog Urol, 2009, 10, 19, iii




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Soulié M., Beuzeboc P., Cornud F., Eschwege P., Gaschignard N., Grosclaude P., et al. Cancer de la prostate Prog Urol 2007 ;  17 : 1157-1230
Draisma G., Postma R., Schröder F.H., van der Kwast T.H., de Koning H.J. Gleason score, age and screening: modeling dedifferentiation in prostate cancer Int J Cancer 2006 ;  119 : 2366-2371 [cross-ref]
Schaeffer E.M., Carter H.B., Kettermann A., Loeb S., Ferrucci L., Landis P., et al. Prostate specific antigen testing among the elderly--when to stop? J Urol 2009 ;  181 : 1606-1614 [cross-ref]
D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., Chen M.H. Cancer-spzcific mortality after surgery or radiation for patients with localized prostate cancer managedduring the prostate-specific antigen era J Clin Oncol 2003 ;  21 : 2163-2172
Nguyen P.L., Chen M.H., Catalona W., Moul J.W., Sun L., D'Amico A.V. Predicting prostate cancer mortality among men with intermediate to high risk disease and multiple unfavorable risk factors Int J Radiat Oncol Biol Phys 2009 ;  73 : 659-664 [cross-ref]
SIOG prostate cancer guidelines.www.cancerworld.org//Cancerworld/getStaticModFile.aspx ? id= é'à_. 2008. Ref Type : Internet Communication.
D'Amico A.V., Hui-Chen M., Renshaw A.A., Sussman B., Roehl K.A., Catalona W.J. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer J Urol 2006 ;  176 : S11-S15
Wong Y.N., Mitra N., Hudes G., Localio R., Schwartz J.S., Wan F., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men JAMA 2006 ;  296 : 2683-2693 [cross-ref]
Fowler J.E., Terrell F.L., Renfroe D.L. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy J Urol 1996 ;  156 : 1714-1718 [cross-ref]
Albertsen P.C., Fryback D.G., Storer B.E., Kolon T.F., Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer J Urol 1996 ;  156 : 127-132 [cross-ref]
Geinitz H., Zimmermann F.B., Thamm R., Schumertl A., Busch R., Molls M. 3D conformal radiation therapy for prostate cancer in elderly patients Radiother Oncol 2005 ;  76 : 27-34 [cross-ref]
Pignon T., Horiot J.C., Bolla M., van Poppel H., Bartelink H., Roelofsen F., et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies Radiother Oncol 1997 ;  42 : 107-120 [cross-ref]
Nguyen T.D., Azria D., Brochon D., Poortmans P., Miller R.C., Scandolaro L., et al. Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: A retrospective rare cancer network study Crit Rev Oncol Hematol 2009 ;
D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 2008 ;  399 : 289-295
Widmark A., Klepp O., Solberg A., Damber J.E., Angelsen A., Fransson P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3):an open randomised phase III trial Lancet 2009 ;  373 : 301-308 [cross-ref]
Pollack A, Li T, Buyyounouski M, Horwitz E, Price R, Ma C, et al. Defining the ⍺/β ratio for prostate cancer: Results of a randomized radiotherapy hypofractionation trial. Proc. ASCO-GU 2009:Abstract N°4.






© 2009 
Elsevier Masson SAS. Tous droits réservés.